| Objective To observe and evalute the clinical therapeutic effects andsafety of tacrolimus-based immunosuppression regimen (FK506+MMF+Pred) after liver transplantation.We hope to find the reasonableindividual medication to reduce the side-effects of drugs and to improve thelife quality and survival rate of recipients.Methods The clinical data of49recipients,who accepted livertransplantation from August2007to November2011in our center,wereretrospectively analyzed.All of them received the tacrolimus-basedimmunosuppression regimen(FK506+MMF+Pred) after operation.Theinitial dose of FK506was2mg each12hours and its blood concentrationwas maintained at8~10ng/ml within the first3months afteroperation,6~8ng/ml within the next3months and4~6ng/ml after6months.The observed indices included the survival status of recipients andgrafts,rejection rate,infection(bacteria, fungus, virus, etc) rates and theoccurrence of FK506side-effects (neurotoxicity, hyperglycemia,hypertension, high cholesterol, renal dysfunction). Result5of49recipients died in the perioperative and the follow-upperiod.Acute rejection occurred in6cases(12.24%) and chronic rejectionoccurred in3cases (6.12%).12cases(24.49%) had infections afteroperation.The side-effects of FK506were neurotoxicity(8cases,16.33%),hyperglycemia(17cases,34.69%), hypertension(7cases,14.29%), highcholesterol(4cases,8.16%) and renal dysfunction(2cases,4.08%).Conclusion The tacrolimus-based immunosuppression regimen(FK506+MMF+Pred) is effective and safe in the prevention and treatmentof acute and chronic rejection. And it’s also resultful to improve thesurvival rates of recipients and liver grafts. We recommed that the bloodconcentration of FK506is maintained at8~10ng/ml within the first3months after operation,6~8ng/ml within the next3months and4~6ng/mlafter6months. In order to reduce the adverse reactions,the dosage ofFK506should be adjusted individually according to recipients’ bloodconcentration,clinical symptoms and laboratory test results. |
PDF Full Text Request